Looking at Novavax’s peers in the therapeutics segment, some have already reported their Q3 results, giving us a hint as to ...

In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change ...

Novavax has had a volatile few years, and the share price history raises a straightforward question for you as an investor.

Novavax, Inc. reported that on October 28, 2026 Sanofi Pasteur Inc. dosed the fifth patient in its Phase 3 influenza-COVID-19 ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026.

Novavax ( ) has provided an announcement. On October 28, 2026, Sanofi Pasteur dosed the fifth patient in its Phase 3 influenza–COVID-19 combination vaccine trial in the European ...

Novavax President and Chief Executive Officer John C. Jacobs said the partnership has generated more than $1 billion in revenue for Novavax to date. He added that the Phase 3 trial represents progress ...

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...

Novavax’s shares are extremely volatile and have had 46 moves greater than 5% over the last year. But moves this big are rare ...